Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Oral Presentation FC46: Effectiveness and tolerability of Buprenorphine for cancer pain - A Cochrane review

Taubert, Mark, Schmidt-Hansen, Mia, Bronham, Nathan and Arnold, Stephanie 2016. Oral Presentation FC46: Effectiveness and tolerability of Buprenorphine for cancer pain - A Cochrane review. Presented at: 9th World Research Congress of the European Association for Palliative Care (EAPC), Dublin, Ireland, 9-11 June 2016. Palliative Medicine. , vol. 6. NP36. 10.1177/0269216316646056

Full text not available from this repository.

Abstract

Objectives: To assess how effective and tolerable Buprenorphine is in the treatment of cancer pain Methods: We searched CENTRAL, MEDLINE, ISI Web of Science, EMBASE, ClinicalTrials.gov, ISI BIOSIS, metaRegister of controlled Trials, WHO International Clinical Trials Registry Platform and the Proceedings of the Congress of the European Federation of International Assc. for the Study of Pain to early 2015 Results: 19 randomised controlled trials comparing buprenorphine with placebo, buprenorpohine or another active drug for cancer pain were included. The trials included 1421 patients and looked at 16 different intervention comparisons. 11 studies compared buprenorphine to another drug. Of these, five, three and three studies, respectively, found Buprenorphine to be superior, no different or inferior to the alternative treatment in side effect profile or patient acceptability. One study identified faster onset of pain relief after sublingual adminstation when compared to the subdermal route, with similar analgesic duration and adverse event rate. Two studies found transdermal buprenorphine superior to placebo, whereas a third study found no difference between placebo and different doses of transdermal buprenorphine. No clear dose-response relationship was found for transdermal buprenorphine. Quality of evidence was limited by small sample sizes, under-reporting and attrition. Conclusions: Buprenorphine can be considered as a fourth line option compared to more conventional cancer pain therapies like morphine, oxycodone and fentanyl. Even then, it is only suitable and effective for some patients.

Item Type: Conference or Workshop Item (Lecture)
Date Type: Publication
Status: Published
Schools: Medicine
ISSN: 0269-2163
Last Modified: 26 Jul 2019 10:36
URI: http://orca.cf.ac.uk/id/eprint/117344

Actions (repository staff only)

Edit Item Edit Item